Full-Time

Scientist II

PKPD Modeler

Posted on 7/22/2024

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$120k - $160kAnnually

Mid

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
R
Requirements
  • A Ph.D. or Pharm.D. with a PKPD Modeling & Simulation background.
  • Extensive hands-on experience using NONMEM modeling software is a must.
  • Familiar with common PKPD/TGI models and able to write customized NONMEM models.
  • Relevant work experience in pharmaceutical companies is preferred but not required. Recent PhD graduates with a good track record of PKPD M&S publications are encouraged to apply.
  • Proficiency in R programming is desired.
  • Able to take dynamically assigned pharmacometrics tasks and deliver the results in a timely manner.
  • Excellent verbal and written communication skills, and ability to clearly convey complex concepts and findings to both non-specialist and specialist audiences.
  • A critical thinker passionate team player and quick learner with high energy who thrives in a dynamic and fast-paced environment.
  • Demonstrated experience and track record in clinical-stage drug development is a big plus but not required.
Responsibilities
  • Establish population PK models to identify intrinsic and extrinsic factors that impact PK, and to guide dose/schedule optimization and recommended phase 2 dose/schedule (RP2Ds) selection.
  • Perform model-based simulations to optimize dosing to inform trial designs and clinical outcomes. Ensure quality and integrity of modeling and simulation results.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

INACTIVE